Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.
Less stringent criteria for gestational diabetes remain predictive of risk for later prediabetes or type 2 diabetes despite identifying a larger number of women, the HAPO FUS investigators report in JAMA.
Advisory Board member Theresa Smyth tackles an emergency case involving a type 2 diabetes patient on a new diet and treated with empagliflozin. What went wrong and how should he be managed? [Read more].
Impaired glucose tolerance in obese youths frequently reverts to normal, although the chances of this happening are strongly influenced by ethnicity, researchers report in The Lancet Child & Adolescent Health.
Findings from a phase IV trial suggest that aspirin use may reduce the risk for primary vascular events but at the cost of increased major bleeding risk in patients with diabetes, while omega-3 fatty acid supplementation does not have a cardioprotective effect.
Is the medical model of care failing diabetes patients in its current form? Advisory Board member Katharine Barnard considers this, and the future of clinical decision support [read more].
A study of the Swedish National Diabetes Register suggests that keeping five cardiovascular risk factor variables within the target ranges could offset the excess risk for death, myocardial infarction, or stroke among patients with type 2 diabetes relative to the general population.
Researchers have found evidence to support an increased risk for amputation among patients with type 2 diabetes taking sodium-glucose cotransporter 2 inhibitors relative to some oral treatments.
Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy [read more].
Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.
This review describes the most effective multidisciplinary approach to weight management in patients with type 2 diabetes in real-world clinical practice [read more]. Hamdy O, Ashrafzadeh S, Mottalib A. Curr Diab Rep 2018; 18: 66. doi: 10.1007/s11892-018-1030-4
The authors assess the risk of hospitalization due to HF with the use of dipeptidyl peptidase-4 inhibitors compared to glucagon like peptide-1 receptor agonists [read more]. Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4
Editorial Board member Lori Berard discusses how to meet and overcome the challenges that follow the initial insulin prescription in patients with type 2 diabetes [listen to the interview 11:53].
Advisory Board member Katharine Barnard scrutinizes the opinion that clinicians should rely on glycemic outcomes when weighing the decision to prescribe a diabetes device [read more].
Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.
Carmen Soto and David Strain provide their insights on clinical inertia in diabetes care and present the co-production model of open communication as an innovative means to address this widespread clinical issue [read more].
This review presents the evidence from old and recent trials relevant to optimal blood pressure levels in diabetes mellitus, aiming to shed light in this major clinical question [read more]. Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5
Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.
A patient discusses their experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease.
These slide sets summarize the results of randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.
Funded by an educational grant from Abbott Diabetes Care
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
